Samsung Pharmaceutical KRX:001360KOSPI
삼성제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days1
Articles tracked1since Sep 11
In Q2 2026, Samsung Pharmaceutical reported revenue of ₩9.9bn, down 9.1% year on year, and an operating loss of ₩5.0bn. Samsung Pharmaceutical (삼성제약) appeared in 1 Korean news article and 1 DART filing over the past seven days. Coverage peaked on Sep 11 with 1 article.
Samsung Pharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩9.9bn | -9.1% | −₩5.0bn | −₩56.6bn |
| Q1 2026 | ₩9.0bn | -20.6% | −₩1.9bn | ₩8.8bn |
| Q4 2025 derived | ₩11.8bn | +12.9% | −₩5.4bn | −₩59.1bn |
| Q3 2025 | ₩12.0bn | +8.3% | −₩3.9bn | −₩30.2bn |
| Q2 2025 | ₩10.9bn | +3.0% | −₩4.3bn | ₩63.6bn |
| Q1 2025 | ₩11.4bn | -6.7% | −₩4.5bn | ₩37.2bn |
| Q4 2024 derived | ₩10.5bn | -12.9% | −₩2.9bn | −₩17.3bn |
| Q3 2024 | ₩11.1bn | -5.4% | −₩3.6bn | ₩18.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Samsung Pharmaceutical top stories 2 weeks, by number of outlets
- 1